Opus Genetics, Inc. (IRD) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 88.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $88.81M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $59.96M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $45.09M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $30.82M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $32.43M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $41.79M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $30.32M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $36.63M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $41.41M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $47.16M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $50.50M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $42.35M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $39.98M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $38.99M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $42.63M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $13.86M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $24.53M | (m) | (m) |
| 2018-12-31 | $14.73M | (m) | $8.74M | $5.98M | (m) |
| 2018-09-30 | $12.57M | (m) | $4.59M | $7.97M | (m) |
| 2018-06-30 | $16.74M | (m) | $5.09M | $11.65M | (m) |
| 2018-03-31 | $21.18M | (m) | $6.30M | $14.88M | (m) |
| 2017-12-31 | $26.83M | (m) | $8.90M | $17.93M | (m) |
| 2017-09-30 | $23.20M | (m) | $8.23M | $14.98M | (m) |
| 2017-06-30 | $26.78M | (m) | $8.79M | $17.99M | (m) |
| 2017-03-31 | $18.50M | (m) | $10.49M | $8.02M | (m) |
| 2016-12-31 | $20.32M | (m) | $11.58M | $8.74M | (m) |
| 2016-09-30 | $21.81M | (m) | $8.39M | $13.42M | (m) |
| 2016-06-30 | $19.40M | (m) | $7.88M | $11.52M | (m) |
| 2016-03-31 | $24.47M | (m) | $10.46M | $14.01M | (m) |
| 2015-12-31 | $23.44M | (m) | $10.20M | $13.24M | (m) |
| 2015-09-30 | $21.46M | (m) | $12.45M | $9.01M | (m) |
| 2015-06-30 | $25.98M | (m) | $9.97M | $16.01M | (m) |
| 2015-03-31 | $29.39M | (m) | $10.73M | $18.66M | (m) |
| 2014-12-31 | $32.70M | (m) | $9.83M | $22.87M | (m) |
| 2014-09-30 | $35.59M | (m) | $14.97M | $20.61M | (m) |
| 2014-06-30 | $38.20M | (m) | $38.10M | $100.00K | (m) |
| 2014-03-31 | $40.17M | (m) | $40.07M | $100.00K | (m) |
| 2013-12-31 | $18.79M | (m) | $18.69M | $100.00K | (m) |
| 2013-09-30 | $14.97M | (m) | $14.87M | $100.00K | (m) |
| 2013-06-30 | $10.08M | (m) | $9.98M | $100.00K | (m) |
| 2013-03-31 | $12.17M | (m) | $12.07M | $100.00K | (m) |
| 2012-12-31 | $13.59M | (m) | $13.49M | $100.00K | (m) |
| 2012-09-30 | $7.48M | (m) | $7.38M | $100.00K | (m) |
| 2012-06-30 | $8.58M | (m) | $8.48M | $100.00K | (m) |
| 2012-03-31 | $10.05M | (m) | $8.10M | $1.95M | (m) |
| 2011-12-31 | $11.81M | (m) | $9.86M | $1.95M | (m) |
| 2011-09-30 | $15.17M | (m) | $13.22M | $1.95M | (m) |
| 2011-06-30 | $18.08M | (m) | $16.13M | $1.95M | (m) |
| 2011-03-31 | (m) | (m) | $20.51M | (m) | (m) |
| 2010-12-31 | $14.79M | (m) | $12.34M | $2.45M | (m) |
| 2010-09-30 | (m) | (m) | $15.83M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $17.81M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $7.30M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $369.13K | (m) | (m) |
| 2001-03-18 | (m) | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |